D
Dibyen Majumdar
Researcher at University of Illinois at Chicago
Publications - 67
Citations - 2238
Dibyen Majumdar is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Optimal design & Melanoma. The author has an hindex of 25, co-authored 67 publications receiving 2033 citations. Previous affiliations of Dibyen Majumdar include Indian Statistical Institute.
Papers
More filters
Journal ArticleDOI
Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.
Tohru Yamada,Masatoshi Goto,Vasu Punj,Olga Zaborina,Olga Zaborina,Mei Ling Chen,Kazuhide Kimbara,Kazuhide Kimbara,Dibyen Majumdar,Elizabeth A Cunningham,Tapas K. Das Gupta,Ananda M. Chakrabarty +11 more
TL;DR: The use of a purified bacterial redox protein, azurin, that enters human cancer (melanoma UISO-Mel-2) cells and induces apoptosis is reported and has been shown to allow regression of human U ISO- Mel-2 tumors xenotransplanted in nude mice and may potentially be used in cancer treatment.
Journal ArticleDOI
Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer
Vasu Punj,Suchita Bhattacharyya,Djenann Saint-Dic,Chenthamarakshan Vasu,Elizabeth A Cunningham,J. M. Graves,Tohru Yamada,Andreas I. Constantinou,Konstantin Christov,Bethany E. Perez White,Gang Li,Dibyen Majumdar,Ananda M. Chakrabarty,Tapas K. Das Gupta +13 more
TL;DR: In conclusion, azurin blocks breast cancer cell proliferation and induces apoptosis through the mitochondrial pathway both in vitro and in vivo, thereby suggesting a potential chemotherapeutic application of this bacterial cupredoxin for the treatment of breast cancer.
Journal ArticleDOI
A first-in-class, first-in-human, phase i trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
Michael A. Warso,Jon M. Richards,D. Mehta,Konstantin Christov,C. M. Schaeffer,L Rae Bressler,Taketo Yamada,Dibyen Majumdar,Scott Kennedy,Craig W. Beattie,T. K. Das Gupta +10 more
TL;DR: Evidence of anti-tumour activity indicates a highly favourable therapeutic index and demonstrates proof of concept for this new class of non-HDM2-mediated peptide inhibitors of p53 ubiquitination.
Journal Article
Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
George I. Salti,Taline Manougian,Miguel Farolan,Anne Shilkaitis,Dibyen Majumdar,Tapas K. Das Gupta +5 more
TL;DR: The data suggest that Mitf may be a new molecular prognostic marker in patients with intermediate-thickness melanoma and findings persisted in multivariate analysis.
Journal ArticleDOI
Optimal designs for comparing test treatments with controls
TL;DR: In this article, existing knowledge on optimal designs for comparing test treatments with controls under 0-, 1-, and 2-way elimination of heterogeneity models is presented. But the results are motivated through numerical examples.